A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis
NCT ID: NCT05366036
Last Updated: 2022-05-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
172 participants
OBSERVATIONAL
2017-06-14
2022-01-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
NCT01930708
Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)
NCT02323269
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
NCT01903291
Tecfidera and the Gut Microbiota
NCT02471560
A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China
NCT05658484
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with MS
Participants with relapsing-remitting MS who are newly prescribed and will start treatment with Tecfidera in a real-world clinical practice setting will be observed prospectively for up to 24 months.
No Intervention
This is a non-interventional study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No Intervention
This is a non-interventional study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. A participant data release consent form is signed and dated by the participant and/or legal representative
3. A Korean participant is diagnosed as relapsing-remitting MS per approved Korean label
Exclusion Criteria
2. Participants with unresolved serious infection
3. Participants who are participating in another study
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Korea Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site #20
Cheonan, Chungcheongnam-do, South Korea
Site #15
Ansan, Gyeonggi-do, South Korea
Site #08
Bucheon-si, Gyeonggi-do, South Korea
Site #09
Goyang-si, Gyeonggi-do, South Korea
Site #14
Goyang-si, Gyeonggi-do, South Korea
Site #23
Changwon, Gyeongsangnam-do, South Korea
Site #13
Jinju, Gyeongsangnam-do, South Korea
Site #02
Busan, , South Korea
Site #16
Busan, , South Korea
Site #01
Daegu, , South Korea
Site #17
Daegu, , South Korea
Site #07
Daejeon, , South Korea
Site #03
Kwangju, , South Korea
Site #04
Seoul, , South Korea
Site #06
Seoul, , South Korea
Site #11
Seoul, , South Korea
Site #12
Seoul, , South Korea
Site #18
Seoul, , South Korea
Site #19
Seoul, , South Korea
Site #21
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MS0008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.